Valeo Pharma begins commercialization of Yondelis, a treatment for soft tissue sarcoma

Valeo Pharma (CSE: VPH) President and CEO Steve Saviuk joined Steve Darling from Proactive with news the company has commenced commercializing Yondelis® in Canada. That product is recognized global standard of care in the treatment of soft tissue sarcoma.
Saviuk talks about when that product will be available and also about some of the other products they company plans to move forward this year.